

Genedrive PLC

08:19 09 Jul 2019

Genedrive 'confident' of WHO approval for hepatitis C test by autumn

Genedrive PLC (LON:GDR) "remains confident" that the World Health Organisation will 'pre-qualify' its HCV ID hepatitis C test within the next few months, despite some delays to the clinical trial.

Part one of the qualification - a quality audit - has already been completed, but part two - an independent clinical trial - is taking longer than expected due to a lack of low viral load samples for analysis.

READ: Genedrive making commercial progress

Still, Genedrive believes the study should complete "in the short term" as more samples become available, and bosses hope to update investors on the result of the qualification in the autumn.

The overall commercialisation of the HCV ID kit is progressing more slowly than expected though, with only 12 country registrations having been completed, below the internal target of 30 before the end of June.

This, coupled with the delays to the WHO qualification process, means Genedrive expects revenue for the year to June 2020 "to fall short" of current forecasts, although growth should still be in double digits.

"We are optimistic about the long-term opportunity that HCV presents and expect commercial uptake to occur during the financial year to 30 June 2020, however the slower rate of country registrations and ongoing WHO pre-qualification process will have an impact on our overall rate of short-term growth," said the company in Tuesday's trading update.

US DoD continues to order

On a more positive note, Genedrive's development of an antibiotic-induced hearing loss test with the NHS is ahead of schedule, with in-hospital trials expected to begin in the autumn after CE marking requirements.

The company pointed out that this screening assay has the potential for distribution across all NHS emergency settings to help prevent hearing loss in children, as well as application in Europe and the rest of the world.

Over in the US, the Department of Defense ordered £900,000 worth of biohazard identification tests last year, and the repeat order is "proof of the platform's utility", according to 'house' broker Peel Hunt.

Importantly, Genedrive "remain[s] positive of forward revenue momentum" with the DoD in the year ahead.


Moving forward, albeit slowly

For the 12 months ended 30 June, revenue rose to £2.4mIn (2018: £1.9mIn), broadly in line with forecasts. At £5.2mIn, cash was ahead of expectations (2018: £5.8mIn).

Price: 21.5

Market Cap: £7.5 m

1 Year Share Price Graph



December 2018 May 2019 December 20

Share Information

Code: GDR

Listing: AIM

52 week High Low
30 13

Sector: Pharma & Biotech

Website: www.genedrive.com

Company Synopsis:

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.

action@proactiveinvestors.com

"The commercialisation of our HCV ID kit is progressing more slowly than we would have hoped," said chief executive David Budd.

"However, we continue to progress WHO pre-qualified status and the registration of the product in our target countries and so reasonably expect an upturn in demand in the future.

"Our supply of Genedrive to the US DoD and its contribution to the year and the outlook for 2019/20 continues to grow; we expect further orders for both assays and units during the forthcoming year."

Shares were down 16.3% to 18p in early deals on Tuesday.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).